Nanoemulgel: a novel nano carrier as a tool for topical drug delivery

MR Donthi, SR Munnangi, KV Krishna, RN Saha… - Pharmaceutics, 2023 - mdpi.com
Nano-emulgel is an emerging drug delivery system intended to enhance the therapeutic
profile of lipophilic drugs. Lipophilic formulations have a variety of limitations, which includes …

Histone modifications in Alzheimer's disease

DA Santana, MAC Smith, ES Chen - Genes, 2023 - mdpi.com
Since Late-onset Alzheimer's disease (LOAD) derives from a combination of genetic variants
and environmental factors, epigenetic modifications have been predicted to play a role in the …

Nanocarrier mediated drug delivery as an impeccable therapeutic approach against Alzheimer's disease

R Taliyan, V Kakoty, KC Sarathlal… - Journal of Controlled …, 2022 - Elsevier
For the past several years, dementia, is one of the predominantly observed groups of
symptoms in a geriatric population. Alzheimer's disease (AD) is a progressive memory …

Mitochondria-targeted delivery strategy of dual-loaded liposomes for Alzheimer's disease therapy

L Vasileva, G Gaynanova, F Valeeva… - International Journal of …, 2023 - mdpi.com
Liposomes modified with tetradecyltriphenylphosphonium bromide with dual loading of α-
tocopherol and donepezil hydrochloride were successfully designed for intranasal …

Preparation and characterization of brain-targeted polymeric nanocarriers (Frankincense-PMBN-lactoferrin) and in-vivo evaluation on an Alzheimer's disease-like rat …

F Moazzam, A Hatamian-Zarmi, BE Hosseinzadeh… - Brain Research, 2024 - Elsevier
Experiments have demonstrated that frankincense may offer protection against scopolamine-
induced Alzheimer's disease by mitigating cholinergic dysfunction and inhibiting …

Brain insulin resistance linked Alzheimer's and Parkinson's disease pathology: an undying implication of epigenetic and autophagy modulation

V Kakoty, S Kc, S Kumari, CH Yang, SK Dubey… - …, 2023 - Springer
In metabolic syndrome, dysregulated signalling activity of the insulin receptor pathway in the
brain due to persistent insulin resistance (IR) condition in the periphery may lead to brain IR …

[HTML][HTML] Pathology of Amyloid-β (Aβ) Peptide Peripheral Clearance in Alzheimer's Disease

A Tsoy, B Umbayev, A Kassenova… - International journal of …, 2024 - mdpi.com
Although Alzheimer's disease (AD) is traditionally viewed as a central nervous system
disorder driven by the cerebral accumulation of toxic beta-amyloid (Aβ) peptide, new …

Therapeutic nanotechnologies for Alzheimer's disease: A critical analysis of recent trends and findings

P Delbreil, JM Rabanel, X Banquy… - Advanced Drug Delivery …, 2022 - Elsevier
Alzheimer's Disease (AD) is an irreversible neurodegenerative disease for which no
modifying therapies are presently available. Besides the identification of pathological …

Exploring Rosiglitazone's Potential to Treat Alzheimer's Disease through the Modulation of Brain-Derived Neurotrophic Factor

ML Nelson, JA Pfeifer, JP Hickey, AE Collins… - Biology, 2023 - mdpi.com
Simple Summary This review focuses on rosiglitazone, a medication used to treat diabetes.
Rosiglitazone lowers blood sugar levels by helping the body use insulin more efficiently …

Rosiglitazone attenuates amyloid beta and glial fibrillary acidic protein in the hippocampus and neuroinflammation associated learning and memory impairments in …

F Beheshti, M Hosseini… - Behavioural Brain …, 2023 - Elsevier
Objective The aim of the current study was to investigate the beneficial effects of
rosiglitazone (Rosi) on amyloid beta (Aβ) and glial fibrillary acidic protein (GFAP) in the …